Literature DB >> 24051043

Cervical cancers associated with human papillomavirus types 16, 18 and 45 are diagnosed in younger women than cancers associated with other types: a cross-sectional observational study in Wales and Scotland (UK).

Ned Powell1, Kate Cuschieri, Heather Cubie, Sam Hibbitts, Dominique Rosillon, Sabrina Collas De Souza, Anco Molijn, Wim Quint, Katsiaryna Holl, Alison Fiander.   

Abstract

BACKGROUND: Most cervical cancers are attributable to infection with one of fourteen types of human papillomavirus (HPV), but HPV types differ in oncogenic potential. Characterisation of cancers associated with specific HPV types is required to predict the likely impact of current prophylactic vaccines and the potential benefits of vaccine formulations including additional HPV types.
OBJECTIVE: The study aimed to correlate HPV type with histology and age at diagnosis, in Invasive Cervical Cancers (ICCs) from two of the devolved countries of the UK (Wales and Scotland). STUDY
DESIGN: Centralised histopathology review and rigorously standardised HPV-DNA typing were applied to 592 ICC diagnosed 2001-2006. HPV status was analysed in relation to histology and age at diagnosis.
RESULTS: HPV infection was confirmed in 535/592 cases. Among the 497 tumours infected with single HPV types, the three most common types were HPV16 (62% 95%CI: 57.6-66.1), HPV18 (18.9% 95%CI: 15.7-22.6) and HPV45 (5.4% 95%CI: 3.7-7.8). HPV16 or 18 were present in 80.9% of HPV positive cases. Women with tumours associated with HPV types 16, 18 and 45 were on average 10.5 years younger at diagnosis than women with tumours associated with other HPV types.
CONCLUSIONS: Prophylactic vaccines targeting HPV16 and 18 could potentially prevent up to 80.9% of ICC in the populations investigated. Cancers associated with HPV16, 18 and 45 were diagnosed at younger ages, supporting the hypothesis of faster progression than for tumours caused by other HPV types.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ADC; ASC; Age; Cervical cancer; Diagnosis; FFPE; H&E; HPV; HR; Human papillomavirus; ICC; SCC; UK; adenocarcinoma; adenosquamous carcinoma; formalin fixed paraffin embedded; haematoxylin and eosin; high risk; human papillomavirus; invasive cervical cancer; squamous cell carcinoma

Mesh:

Year:  2013        PMID: 24051043     DOI: 10.1016/j.jcv.2013.08.020

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  7 in total

1.  Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine.

Authors:  Ricardo Rosales; Mario López-Contreras; Carlos Rosales; Jose-Roberto Magallanes-Molina; Roberto Gonzalez-Vergara; Jose Martin Arroyo-Cazarez; Antonio Ricardez-Arenas; Armando Del Follo-Valencia; Santiago Padilla-Arriaga; Miriam Veronica Guerrero; Miguel Angel Pirez; Claudia Arellano-Fiore; Freddy Villarreal
Journal:  Hum Gene Ther       Date:  2014-12       Impact factor: 5.695

2.  Alinity m HR HPV Assay Fulfills Criteria for Human Papillomavirus Test Requirements in Cervical Cancer Screening Settings.

Authors:  Anja Oštrbenk Valenčak; Anja Šterbenc; Katja Seme; Mario Poljak
Journal:  J Clin Microbiol       Date:  2019-12-23       Impact factor: 5.948

3.  Distinctive distribution of HPV genotypes in cervical cancers in multi-ethnic Suriname: implications for prevention and vaccination.

Authors:  M G Grunberg; M Chan; M R Adhin
Journal:  Epidemiol Infect       Date:  2016-10-20       Impact factor: 4.434

4.  HPV mRNA is more specific than HPV DNA in triage of women with minor cervical lesions.

Authors:  Sveinung Wergeland Sørbye; Silje Fismen; Tore Jarl Gutteberg; Elin Synnøve Mortensen; Finn Egil Skjeldestad
Journal:  PLoS One       Date:  2014-11-18       Impact factor: 3.240

Review 5.  Systematic review of cost-effectiveness analyses for combinations of prevention strategies against human papillomavirus (HPV) infection: a general trend.

Authors:  Frédéric Gervais; Kyle Dunton; Yiling Jiang; Nathalie Largeron
Journal:  BMC Public Health       Date:  2017-03-28       Impact factor: 3.295

6.  Quality control of cervical cytology using a 3-type HPV mRNA test increases screening program sensitivity of cervical intraepithelial neoplasia grade 2+ in young Norwegian women-A cohort study.

Authors:  Bjørn Westre; Anita Giske; Hilde Guttormsen; Sveinung Wergeland Sørbye; Finn Egil Skjeldestad
Journal:  PLoS One       Date:  2019-11-05       Impact factor: 3.240

7.  Primary cervical cancer screening with an HPV mRNA test: a prospective cohort study.

Authors:  Sveinung Wergeland Sørbye; Silje Fismen; Tore Jarl Gutteberg; Elin Synnøve Mortensen; Finn Egil Skjeldestad
Journal:  BMJ Open       Date:  2016-08-11       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.